Gentium Shareholders Sue to Stop Jazz Pharmaceuticals Deal

Gentium SpA’s board was sued by shareholders seeking to stop Jazz Pharmaceuticals Plc from buying the rare-disease drug developer because they claim the $1 billion deal is “hopelessly flawed.”

To continue reading this article you must be a Bloomberg Professional Service Subscriber.